News & Events
News
Gate2Brain Receives EMA Orphan Drug Designation for Its Groundbreaking Pediatric Cancer Treatment
Gate2Brain, has reached a major milestone in the fight against pediatric brain tumors by obtaining Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for its innovative product, G2B-002.
Interviews
Manel González-Piñero
Headof Innovation at CREB UPC and XarTEC SALUT
"Our main objectives are to develop a technologies map of the members of XarTEC SALUT and to find the most effective ways to support them."
The Research Centre for Biomedical Engineering (CREB) at the UPC, an institution affiliated with the Institut de Recerca Sant Joan de Déu (IRSJD), received top funding in 2020 from the European Regional Development Fund (ERDF), under the management of the Government of Catalonia, to create and coordinate XarTEC SALUT, Catalonia's first health technologies innovation and valorisation network.
Agenda
#ViernesCientíficos | Diseño de un dispositivo de contención neonatal: Innovación enfermera
Seminario a cargo de Silvia Vicente Pérez. Enfermera Especialista en Pediatría. Experta en innovación en el ámbito de la salud y profesora titular de l'Escola Universitària d'Infermeria Sant Pau de Barcelona.
Defensa tesi doctoral: Leire Balaguer Lluna
"Inhibition of the PI3K/Akt pathway as a therapeutic strategy for pediatric-type diffuse high-grade gliomas"
Communications office
Marta Fortuny
93 253 21 67
marta.fortuny@sjd.es